Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | = 11 nM | In vitro binding affinity of the compound against human glucocorticoid receptor (GR) | ChEMBL. | 15026058 |
Activity (binding) | = 11 nM | In vitro binding affinity of the compound against human glucocorticoid receptor (GR) | ChEMBL. | 15026058 |
Activity (binding) | > 5000 nM | In vitro binding affinity against progesterone receptor | ChEMBL. | 15026058 |
Activity (binding) | > 5000 nM | In vitro binding affinity against progesterone receptor | ChEMBL. | 15026058 |
Efficacy (functional) | = 13 % | Transcriptional activation in CV-1 cells expressing glucocorticoid receptor compared to dexamethasone | ChEMBL. | 15026058 |
Efficacy (functional) | = 13 % | Transcriptional activation in CV-1 cells expressing glucocorticoid receptor compared to dexamethasone | ChEMBL. | 15026058 |
Efficacy (functional) | = 49 % | Repression of transcriptional activity in CV-1 cells expressing glucocorticoid receptor compared to dexamethasone | ChEMBL. | 15026058 |
Efficacy (functional) | = 49 % | Repression of transcriptional activity in CV-1 cells expressing glucocorticoid receptor compared to dexamethasone | ChEMBL. | 15026058 |
IC50 (functional) | = 320 nM | Inhibition of transcriptional repression in CV-1 cells expressing glucocorticoid receptor | ChEMBL. | 15026058 |
IC50 (functional) | = 320 nM | Inhibition of transcriptional repression in CV-1 cells expressing glucocorticoid receptor | ChEMBL. | 15026058 |
IC50 (functional) | > 5000 nM | Inhibition of transcriptional activation in CV-1 cells expressing glucocorticoid receptor | ChEMBL. | 15026058 |
IC50 (functional) | > 5000 nM | Inhibition of transcriptional activation in CV-1 cells expressing glucocorticoid receptor | ChEMBL. | 15026058 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.